Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377111 | 0.85 | VCAM1 (0.73) | ATMTDP1VCAM1KMT2AMEN1 | |
| SCHEMBL3813276 | 0.82 | VCAM1 (0.50) | VCAM1KMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL27752714 | 0.81 | TDP1 (0.58) | ATMTDP1VCAM1KMT2AMEN1 | |
| SCHEMBL18894159 | 0.81 | ATM (0.58) | ATMTDP1VCAM1KMT2AMEN1 | |
| SCHEMBL1178892 | 0.81 | CA2 (0.61) | ATMTDP1VCAM1ALDH1A1CA1 | |
| SCHEMBL30323188 | 0.81 | ATM (0.58) | ATMTDP1VCAM1KMT2AMEN1 | |
| SCHEMBL25252706 | 0.80 | VCAM1 (0.51) | ATMTDP1VCAM1KMT2AMEN1 | |
| SCHEMBL10531067 | 0.80 | MAPK1 (0.56) | ATMTDP1VCAM1ALDH1A1HIF1A | |
| SCHEMBL30489366 | 0.80 | VCAM1 (0.51) | ATMTDP1VCAM1KMT2AMEN1 | |
| SCHEMBL5925285 | 0.79 | MMP1 (0.65) | TDP1VCAM1CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071469-A | PARG inhibitor and preparation method and application thereof | 烟台新药创制山东省实验室 | 2026-05-22 | — | — | CN | disclosed |
| CN-122029163-A | Chemical for targeting chromatin remodeling complexes and uses thereof | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | disclosed |
| US-12559455-B2 | Compound as a UBR box domain ligand | AUTOTAC INC. (KR) | 2026-02-24 | — | — | US | disclosed |
| EP-4687885-A2 | PREVENTION/TREATMENT OF ISCHEMIC REPERFUSION INJURY | Rev Therapeutics (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4615833-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| CN-120152967-A | Bifunctional compounds containing 2, 5-substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250177396-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2025-06-05 | — | — | US | disclosed |
| WO-2025075967-A1 | CHEMICAL MATTERS FOR TARGETING CHROMATIN REMODELING COMPLEXES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4532473-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| CN-1653053-A | Broadspectrum substituted benzimidazole sulfonamide HIV protease inhibitors | TIBOTEC PHARM LTD (IE) | 2005-08-10 | — | — | CN | disclosed |
| US-20050171175-A1 | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD (IE) | 2005-08-04 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1485358-A1 | BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076413-A1 | BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | ATM 2563/4885TDP1 885/4885VCAM1 2020/4885 |
| US-20250177396-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | PLK4, PLK2, PLK3 | ATM 667/4885TDP1 256/4885VCAM1 4567/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | ATM 2563/4885TDP1 885/4885VCAM1 2020/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | ATM 3084/4885TDP1 1386/4885VCAM1 3367/4885 |
| US-12559455-B2 | Compound as a UBR box domain ligand | UBR4, UBTF, UBQLN1 | ATM 3966/4885TDP1 3804/4885VCAM1 1955/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ATM 2338/4885TDP1 223/4885VCAM1 3092/4885 |
| US-20050171175-A1 | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors | CYP2S1, CYP2C8, PRSS8 | ATM 4812/4885TDP1 3993/4885VCAM1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.